Alvotech
http://www.alvotech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alvotech
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Alvotech Lauds Development, Manufacturing Platform As Ustekinumab Wins US Approval
Alvotech’s high confidence for FDA approval for its Stelara biosimilar has been justified, as the Icelandic firm announced only the second US approval for a rival to J&J’s Stelara powerhouse brand, ahead of market formation in 2025.
Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars
Boehringer Ingelheim’s decision not only reflects the company’s difficulties in gaining traction for the first interchangeable version of adalimumab, but also the wider problems for Humira biosimilars in the US.
Alvotech Willing And Able To Go Stride For Stride On Pembrolizumab Manufacturing
Alvotech stepped into its 2023 annual financing results call bursting with positive news and momentum, on the back of obtaining USFDA approval for its biosimilar Humira product and a bullish outlook for its strong pipeline of biosimilar candidates.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Alvotech Iceland
- Alvotech Germany GmnH
- Alvotech Swiss AG
- Glycothera
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice